Listen to the article
0:00
0:00
OMER, Israel, Feb. 2, 2026 /PRNewswire/ — Pulsenmore Ltd. (NASDAQ: PLSM) (TASE: PLSM), a pioneer in home ultrasound technology, today announced a first commercial engagement with a medical center in the United States, following receipt of FDA approval for its home pregnancy ultrasound product.
At the end of January 2026, the Company (through its subsidiary) entered into a services agreement with the Center for Fetal Medicine & Women’s Ultrasound, a fetal medicine and women’s ultrasound center located in LA California (the „CFFM“).
Den vollständigen Artikel hier lesen
6 Kommentare
Solid analysis. Will be watching this space.
I’ve been following this closely. Good to see the latest updates.
Good point. Watching closely.
Great insights on Fonds-News. Thanks for sharing!
This is very helpful information. Appreciate the detailed analysis.
Interesting update on Pulsenmore Announces First Commercial Engagement with a Leading U.S.-Based Medical Center. Looking forward to seeing how this develops.